Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Autoimmune lymphoproliferative syndrome pathophysiology
Introduction
Overview
Overview
Autoimmune lymphoproliferative syndrome(ALPS) is the first disease in human beings which are caused by apoptosis defect. Defect in FAS signaling cause benign chronic lymphoproliferation followed by accumulation of TCRαβ(+) CD4(-) CD8(-) double-negative T (DNT) cells. FAS also prevent the mailgnant proliferation of lymphocytes , so ALPS patients are at higher risk of developing lymphoma.There is an identified genetic defect in 2/3 rd of the total cases of ALPS. Germline mutation is the most common type. Somatic mutation, mutations in the proteins of FAS ligand(FASL) and caspase are also responsible in some cases.The pathogenesis of ALPS is still not very clear and research is ongoing.
Pathophysiology
Pathophysiology
Associated Conditions
- Autoimmune cytopenias: Most common. Can be mild to very severe. Can be intermittent or chronic.[1]
- Autoimmune Hemolytic Anemia
- Autoimmune Neutropenia
- Autoimmune Thrombocytopenia
- Other: Can affect any organ system similar to systemic lupus erythematosis (most rare affecting <5% of patients)
- Nervous: Autoimmune cerebellar ataxia; Guillain-Barre; Transverse myelitis
- GI: Autoimmune esophagitis, gastritis, colitis, hepatitis, pancreatitis
- Derm: Urticaria
- Pulmonary: Bronchiolitis obliterans
- Renal: Autoimmune glomerulonephritis, nephrotic syndrome
- Cancer: Secondary neoplasms affect approximately 10% of patients. True prevalence unknown as <20 reported cases of cancer. Most common EBER+ Non-Hodgkin’s and Hodgkin’s lymphoma
Microscopic Pathology
Microscopic Pathology
Histopathological study findings can be helpful to diagnose Autoimmune lymphoproliferative syndrome. The findings are
- Paracortical expansion with infiltration of polyclonal TCR α/β+ DNT cells.[2]
- DNT cells express TIA-1 and CD57, CD45RO negative
- Follicular hyperplasia
- Polyclonal plasmacytosis
- Spleen has expanded T cell areas dominated by DNT cells.
References
References
- ↑ Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH; et al. (2005). “Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)”. Blood. 105 (6): 2443–8. doi:10.1182/blood-2004-09-3542. PMID 15542578.
- ↑ Li, Pu; Huang, Ping; Yang, Ye; Hao, Mu; Peng, Hongwei; Li, Fei (2015). “Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS)”. Clinical Reviews in Allergy & Immunology. 50 (1): 55–63. doi:10.1007/s12016-015-8466-y. ISSN 1080-0549.
- ↑ 3.0 3.1 Lim, Megan S.; Straus, Stephen E.; Dale, Janet K.; Fleisher, Thomas A.; Stetler-Stevenson, Maryalice; Strober, Warren; Sneller, Michael C.; Puck, Jennifer M.; Lenardo, Michael J.; Elenitoba-Johnson, Kojo S.J.; Lin, Albert Y.; Raffeld, Mark; Jaffe, Elaine S. (1998). “Pathological Findings in Human Autoimmune Lymphoproliferative Syndrome”. The American Journal of Pathology. 153 (5): 1541–1550. doi:10.1016/S0002-9440(10)65742-2. ISSN 0002-9440.
Editor-In-Chief: David Teachey, MD [1] Sharmi Biswas, M.B.B.S